ZYDELIG is used when follicular lymphoma returns after treatment with at least 2 prior medicines. ZYDELIG was approved based on response rates. Data are not yet available to show if ZYDELIG improves symptoms or survival. ZYDELIG should not be used as the first medicine to treat people who have been diagnosed with follicular lymphoma, and should not be used in combination with bendamustine and/or Rituxan® (rituximab) to treat people with follicular lymphoma.
Although follicular lymphoma is not curable, your doctor can use different therapies or combinations of therapies to slow the growth of your follicular lymphoma cells and provide you with periods of remission.2
ZYDELIG works differently from chemotherapy because it blocks a specific protein in B cells called PI3K delta. PI3K delta sends signals to cancerous B cells telling them to multiply and helping them survive. ZYDELIG blocks these signals, helping to slow the growth of lymphoma cells.3,4
At least 50% of the people with relapsed follicular lymphoma had been treated with 4 or more prior therapies, and all of them had relapsed within 6 months of being treated with rituximab and chemotherapy.
The safety profile of ZYDELIG has also been established in people with relapsed follicular lymphoma.View the safety profile
*IntrinsiQ data from May 2015-December 2017.